The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA) have partnered to create a coordinated fast-track pathway for medical innovations.

• Joint Advice: The “Innovation Corridor” allows developers to engage both regulators simultaneously for early advice on clinical trial design and evidence requirements.
• Strategic Focus: The partnership prioritises breakthrough therapies in oncology, neurodegenerative diseases, obesity, and advanced diagnostics.
• Operational Model: Initial testing of the framework will be conducted in collaboration with biotech firm Flagship Pioneering to refine the simultaneous assessment process. 

This summary is based on a press release issued by the Health Sciences Authority.